Drug intelligence / Profile preview

XYL-1001

Development stage: Preclinical
Lead developer: Xylo Bio
Modality: Classical Binding Small Molecules → Small Molecules

Overview

XYL-1001 is a non-hallucinogenic small molecule neuroplastogen developed by Xylo Bio (formerly Psylo). It is designed to rewire neural circuits and restore brain function without inducing hallucinatory effects. The drug acts as a serotonin 5-HT2A receptor agonist and is being developed primarily for the treatment of depressive disorders and other neurological or psychiatric conditions. As a new chemical entity (NCE), XYL-1001 represents an innovative approach in neurotherapeutics aimed at addressing underlying dysfunctions rather than merely managing symptoms. The compound is currently in preclinical development with first-in-human clinical trials planned for mid-2026[1][2][3][4][7][9].

Other names: XYL-1001XYL1001XYL 1001PSYLO 1001PSYLO1001PSYLO-1001

Targets

HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on XYL-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XYL-1001.

Explore the full profile